Safety, efficacy, and tolerability of alemtuzumab in pediatric patients with active relapsing-remitting multiple sclerosis: The LemKids study
Alemtuzumab treatment was associated with a low number of new/enlarging T2 lesions in pediatric patients with RRMS and was safe and well tolerated in seven patients during infusion and the initial 4 months.
Authors
- Stéphanie Jurgensen
- Magdalena Chirieac
- Tanuja Chitnis (ORCID: https://orcid.org/0000-0002-9897-4422)
- Douglas Lorne Arnold (ORCID: https://orcid.org/0000-0003-4266-0106)
- Wenruo Hu
- Eva Havrdová (ORCID: https://orcid.org/0000-0002-9543-4359)
- Pierre Quartier (ORCID: https://orcid.org/0000-0002-1769-549X)
Institutions
- Hôpital Necker-Enfants Malades (FR)
- Harvard University (US)
- Université Paris Cité (FR)
- Charles University (CZ)
- Massachusetts General Hospital (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- Sanofi (United States) (US)
- NeuroRx Research (Canada) (CA)
- Sanofi (China) (CN)
- McGill University (CA)
Publication Details
- Journal
- Multiple Sclerosis Journal
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1177/13524585241295554
- Citations
- 8
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 3.40